Table 3.
Uni- and multivariate analysis of progression-free survival.
| Factors | n | HR 1 | 95% CI 1 | p Value 1 | HR 2 | 95% CI 2 | p Value 2 |
|---|---|---|---|---|---|---|---|
| Clinical | |||||||
| Sex (male/female) | 21/15 | 1.34 | 0.66–2.69 | 0.4164 | |||
| Age (≥60/<60) | 18/18 | 1.13 | 0.57–2.25 | 0.7191 | |||
| Histologic Grade (high/low) | 3/33 | 1.61 | 0.48–5.46 | 0.4422 | |||
| Metastatic pattern (meta/syn) | 17/19 | 1.19 | 0.60–2.35 | 0.6144 | |||
| Primary Tumor site (rectum/colon) | 15/21 | 2.11 | 1.04–4.26 | 0.0377 | 2.56 | 1.23–5.32 | 0.0118 |
| Number of metastatic sites (>1/1) | 15/21 | 1.01 | 0.51–2.01 | 0.9757 | |||
| Treatment regimen (2nd line/1st line) | 4/32 | 0.77 | 0.27–2.20 | 0.6274 | |||
| Genetic | |||||||
| PTPRT/PTPRD deleterious alteration (yes/no) | 10/26 | 2.67 | 1.23–5.80 | 0.0130 | 3.33 | 1.47–7.54 | 0.0038 |
HR: hazard ratio. 1 Univariate analysis. 2 Multivariate analysis.